E-Mail
IMAGE: Last year, researchers used a mouse model that included immune-reactive T cells from patients with Crohn s disease in a proof-of-principle demonstration that a flagellin-directed immunotherapy might provide similar benefits in. view more
Credit: UAB
BIRMINGHAM, Ala. - Last year, Charles O. Elson, M.D., demonstrated a potential preventive treatment for Crohn s disease, a form of inflammatory bowel disease. He used a mouse model that included immune-reactive T cells from patients with Crohn s disease in a flagellin peptide-specific immunotherapy. This study provided proof-of-principle that a flagellin-directed immunotherapy might provide similar benefits in patients.
Now University of Alabama at Birmingham researchers have moved a step closer to possible clinical testing of this treatment, say Elson and co-first authors Katie Alexander, Ph.D., and Qing Zhao, M.D., Ph.D. Their study, published in the journal